Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 9, 1997, Pages 1822-1829

  Tuck, Catherine H ^a   Holleran, Stephen ^a   Berglund, Lars ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

Apolipoprotein(a); Conjugated equine estrogens; Hormone replacement therapy

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA1 GLYCOPROTEIN; APOLIPOPROTEIN A1; CONJUGATED ESTROGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PLACEBO; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HORMONAL REGULATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030751046     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.9.1822     Document Type: Article

References (19)

1. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenbcrg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540-2544.
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
3. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
4. Fairer M, Game FL, Albers CJ, Neil HAW, Winocour PH, Laker MF, Adams PC, Alberti GMM. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb. 1994;14:1272-1283.
5. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
6. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
7. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial. JAMA. 1994;271:999-1003.
8. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548.
9. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991:89:59-67.
10. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
11. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
13. Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet. 1992;90:220-230.
14. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A. 1993;90:1369-1373.
15. Lawn RM. The apolipoprotein(a) gene: characterization of 5′ flanking regions and expression in transgenic mice. Chem Phys Lipids. 1994;67/68:19-23.
16. Wade DP, Lindahl GE, Lawn RM. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1α. J Biol Chem. 1994;269:19757-19765.
17. Mooser V, Mancini FP, Bopp S, Petho-Schramm A, Guerra R, Boerwinkle E, Muller HJ, Hobbs HH. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet. 1995;4:173-181.
18. Trommsdorff M, Kochl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, Lemming L, Klausen IC, Faergeman O, Utermann G, Kraft HG. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest. 1995;96:150-157.
19. Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol. 1995;14:58-64.